history of semaglutide Embracing Evolution- The Pioneering for Sustainable Weight Loss GLP-1R Agonists for Weight Loss

Lu J et al

The same trial found no serious adverse effects, no liver toxicity, and no kidney problems

Haselkorn T, Fish JE, Chipps BE, Miller DP, Chen H, Weiss ST

The SELECT trial and other cardiovascular outcome trials have indicated that Semaglutide can lower the incidence of these events in high-risk populations, offering protective cardiovascular effects beyond glucose control

Drawing on patient research, UK prescribing trends and launch patterns observed in the United States, Simple Online Healthcare estimates oral GLP-1 treatments could reach 120,000-130,000 UK patients within the first three months of launch, with around 100,000 expected to be entirely new to obesity management medication